Last reviewed · How we verify
Efficacy and Cost-effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease
Research Aims The aims of this research study are to determine whether cost-free smoking cessation pharmacotherapy: 1. Helps smokers with Transient Ischemic Attack (TIA) or stroke to quit smoking over the long-term, compared to simply providing a prescription for these medications; 2. Is a more cost-effective alternative to providing a prescription only for these medications in this high risk population. Hypotheses to be Tested The hypotheses to be tested include the following: 1. The CO-validated continuous abstinence rate at weeks 26 and 52 following a target quit date will be at least 10% higher for the cost-free smoking cessation pharmacotherapy intervention group compared to the prescription only usual care group; 2. Cost-free smoking cessation pharmacotherapy will have a greater cost-effectiveness (i.e., cost/quit) than providing a prescription only.
Details
| Lead sponsor | Ottawa Heart Institute Research Corporation |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 194 |
| Start date | 2009-12 |
| Completion | 2015-04 |
Conditions
- Cerebrovascular Disorders
- Smoking Cessation
Interventions
- Cost-Free Pharmacotherapy Group
- Prescription Only Group
Primary outcomes
- The primary outcome will be the biochemically confirmed (exhaled CO < 10 ppm) self-reported continuous abstinence from weeks 12 to 52 following the target quit date. — 52 weeks
Countries
Canada